Serum level of TNF-α receptor type II better correlates with severity of Crohn's disease than other cytokines and conventional clinical activity Indicators;Surowicze stȩżenie receptora typu II dla TNF-α wykazuje lepsza̧ korelacjȩ z ciȩżkościa̧ choroby Leśniowskiego-Crohna niż inne cytokiny i konwencjonalne wskaźniki aktywności choroby

Polski Merkuriusz Lekarski

Volumn 28, Issue 168, 2010, Pages 454-458

  Kohut, Maciej ^a   Kacperek Hartleb, Teresa ^a   Sojka, Dorota ^b   Hartleb, Marek ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Helimed Diagnostic Imaging Sp z oo   (Poland)

Author keywords

Crohn's disease; Interleukins; Magnetic resonance enteroclysis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD; CROHN DISEASE; FEMALE; HOSPITALIZATION; HUMAN; ILEITIS; METABOLISM; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; CYTOKINES; FEMALE; HUMANS; ILEITIS; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77954662031     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Best W.R., Becktel J.M., Singleton J.W. Kern F. Jr.: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 1976, 70, 439-444.
2. Cellier C., Sahmoud T., Froguel E. i wsp.: Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut, 1994, 35, 231-235.
3. Crama-Bohbouth G., Pena A.S., Biemond I.: Are activity indices helpful in assessing active intestinal inflammation In Crohn's disease? Gut, 1989, 30. 1236-1240.
4. de Dombal F.T., Softley A.: IOIBD report no 1, Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut, 1987, 28, 474-481.
5. Filik L., Dagli U., Ulker A.: C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther., 2006, 23, 655-662.
6. Florie J., Horsthuis K., Hommes D.W. i wsp.: Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin. Gastroenterol. Hepatol., 2005, 3, 1221-1228.
7. Florin T.H., Paterson E.W., Fowler E.V. i wsp.:. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand. J. Gastroenterol., 2006, 41, 306-311.
8. Gardiner K.R., Halliday M.I., Barclay G.R.: Significance of systemic endotoxaemia in inflammatory bowel disease. Gut, 1995, 36, 897-901.
9. Gisbert J.P., Gonzalez-Lama Y., Mate J.: Role of biological markers in inflammatory bowel disease. Gastroenterol. Hepatol., 2007, 30, 117-129.
10. Grzybowska-Chlebowczyk U., Woś H., Gabryel B. i wsp.: Ocena stěżeń TNF-α w surowicy dzieci z nieswoistymi zapaleniami jelit. Przegl. Gastroenterol. 2008. 3, 149-153.
11. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology, 1989, 96, 804-810.
12. Hadzlselimovic F.: Urinary excretion of TNF receptors. Gut, 1996, 38, 153-154.
13. Horsthuis K, Bipat S, Stokkers PC, Stoker J. Magnetic resonance imaging for evaluation of disease activity in Crohn's disease, a systematic review. Eur. Radiol., 2009, 19, 1450-1460.
14. Hyams J., Treem W., Eddy E.: Tumor necrosis factor is not elevated in children with inflammatory bowel disease. J. Pediatr. Gastroenterol., 1991, 12, 233-236.
15. Irvine E.J., Feagan B., Rochon J. i wsp.: Quality of life, a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology, 1994, 106, 287-296.
16. Jones J., Loftus E.V. Jr., Pannacione R., i wsp.: Relationship between disease activity and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. Hepatol., 2008, 6, 1218-1224.
17. Langhorst J., Elsenbruch S., Koelzer J. i wsp.: Noninvasive markers in the assessment of intestinal inflammation in IBD, performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. Am. J. Gastroenterol., 2008, 103, 162-169.
18. Ling P.R., Schwartz J.H., Jeevanandam M.: Metabolic changes in rats during a continuous infusion of recombinant interleukin-1. Am. J. Physiol., 1996, 270, E305-E312.
19. MacDonald T.T., Hutchlngs P., Choy M.Y.: Tumor necrosis factor and Interferon-gamma production measured at single cell level in normal and Inflamed human intestine. Clin. Exp. Immunol., 1990, 81, 301-305.
20. Mackiewicz A., Schooltink H., Heinrich P.C.: Soluble IL-6 receptor upregulates expression of acute-phase proteins. J. Immunol., 1992, 149, 2021-2027.
21. Maeda M., Watanabe N., Neda H.: Serum TNF-α activity in inflammatory bowel disease. Immunopharmacol. Immunotoxicol., 1992, 14, 451-461.
22. Mahida Y.R., Kurlac L., Gallagher A.: High circulating concentrations of IL-6 In active Crohn's disease but not ulcerative colitis. Gut, 1992, 32, 1531-1534.
23. Martinez-Borra J., Lopez-Larrea C., Gonzalez S. i wsp.: High serum tumor necrosis factor-alpha levels are associated with lack of response to Infliximab in fistulizing Crohn's disease. Am. J. Gastroenterol., 2002, 97, 2350-2356.
24. Mary J.Y., Modigliani R.: Development and validation of an endoscopic index of the severity for Crohn's disease, a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut, 1989, 30, 983-989.
25. Mazlám M.Z., Hodgson H.J.F.: Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut, 1992, 33, 773-778.
26. Mitsuyama K., Toyonaga A., Sasaki E.: Soluble IL-6 receptor In inflammatory bowel disease, relation to circulating IL-6. Gut, 1995, 36, 45-49.
27. Modigliani R., Mary J.Y., Simon J.F. I wsp.: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology, 1990, 98, 811-818.
28. Nancey S., Hamzaoul N., Moussata D. i wsp.: Serum interieukin-6, soluble interieukin-6 receptor and Crohn's disease activity. Dig. Dis. Sci., 2008, 53, 242-247.
29. Niederau C., Backmerhoff F.: Schumacher B. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology, 1997, 44, 90-107.
30. Nielsen O.H., Vainer B., Madsen S.M.: Established and emerging biological activity markers of Inflammatory bowel disease. Am. J. Gastroenterol., 2000, 95, 359-367.
31. Olson A.D., Ayass M., Chensue S.: Tumor necrosis factor and IL-1β expression in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr., 1993, 16, 241-246.
32. Resna-Lenart S., Barrett K.E.: Probiotics and commensals reverse TNFα and INFy induced dysfunction in human intestinal epithelial cells. Gastroenterology, 2006, 130, 731-746.
33. Rimola J., Rodriguez S., García-Bosch O. i wsp.: Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut, 2009, 58, 1113-20.
34. Rodgers A.D., Cummins A.G.: CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig. Dis. Sci., 2007, 52, 2063-2068.
35. Sategna-Guidetti C., Pulitano R., Fenogli L.: Tumor necrosis factor:cachectin in Crohn's disease. Relation of serum concentration to disease activity. Recent Prog. Med., 1993, 84, 93-99.
36. Shine B., Berghouse L., Jones J.E. i wsp.: C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin. Chim. Acta, 1985, 148, 105-109.
37. Silverberg M.S., Satsangi J., Ahmad T. i wsp.: Toward an Integrated clinical, molecular and serological classification of inflammatory bowel disease, Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol.., 2005, 19, suppl. A, 5-36.
38. Sipponen T., Savilahti E., Kolho K.L. i wsp.: Crohn's disease activity assessed by fecal calprotectin and lactoferin, correlation with CDAI and endoscopic findings. Inflamm Bowel Dis., 2008, 14, 40-46.
39. Sostegni R., Daperno M., Scaglione N. i wsp.: Crohn's disease, monitoring disease activity. Aliment Pharmacol. Ther., 2003, 2, 11-17.
40. Stronkhorst A., Jansen J., Tytgat G.: Soluble IL-2 anf TNF receptors p55 and p75 in Crohn's disease. Gastroenterology, 1994, 106, A779.
41. Sugi K., Saitoh O., Hirata I.: Fecal lactofenin as a marker for disease activity in inflammatory bowel disease, comparison with other neutrophilderived proteins. Am. J. Gastroenterol., 1996, 91, 927-934.
42. Van Assche G., Vermeire S., Rutgeerts P.: The potential for disease modification In Crohn's disease. Nat Rev. Gastroenterol. Hepatol., 2010, 7, 79-85.
43. Van Dullemen H.M., van Deventer S.J., Hommes D.W.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibodies (aA2). Gastroenterology, 1995, 109, 129-135.
44. Yamamoto T., Umegae S., Kitagawa T., Matsumoto K.: Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse. Aliment Pharmacol. Ther., 2004, 19, 671-678.